TrialScientific reports2026

Effect and safety of tislelizumab combined with anlotinib and radiotherapy in advanced hepatocellular carcinoma: A single-arm, single-center, phase II clinical study.

Huaxi Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.